Sofgen Pharma S.A. (PROCF)

OTCMKTS · Delayed Price · Currency is USD
0.0242
-0.0009 (-3.59%)
At close: Feb 10, 2026
-97.84%
Market Cap 55.75M
Revenue (ttm) 423.75M
Net Income (ttm) 40.34M
Shares Out 2.30B
EPS (ttm) 0.40
PE Ratio 0.06
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 232
Average Volume 1,106
Open 0.0242
Previous Close 0.0251
Day's Range 0.0242 - 0.0242
52-Week Range 0.0101 - 1.5000
Beta 63.09
RSI 46.58
Earnings Date May 15, 2026

About Sofgen Pharma

Sofgen Pharma S.A., together with its subsidiaries, develops, produces, and markets pharmaceutical solutions in South America, Central America, North America, and Europe. It operates in five segments: NextGel, Procaps Colombia, Central America North (CAN), Central America South and North Andes (CASAND), and Diabetrics. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision car... [Read more]

Sector Healthcare
Founded 1977
Employees 5,000
Stock Exchange OTCMKTS
Ticker Symbol PROCF
Full Company Profile

Financial Performance

In 2023, Sofgen Pharma's revenue was $423.75 million, an increase of 5.10% compared to the previous year's $403.20 million. Earnings were $40.34 million, an increase of 11.67%.

Financial Statements

News

There is no news available yet.